Details of the Drug

General Information of Drug (ID: DMKE7L9)

Drug Name
Doxacurium
Synonyms
Nuromax; Chlorure de doxacurium; Chlorure de doxacurium [French]; Cloruro de doxacurio; Cloruro de doxacurio [Spanish]; Doxacurii chloridum; Doxacurii chloridum [Latin]; Doxacurium chloride(no stereochemistry); Nuromax (TN); Doxacurium chloride (USAN/INN); Bis[3-[6,7,8-trimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-3,4-dihydro-1H-isoquinolin-2-ium-2-yl]propyl] butanedioate; Bis[3-[6,7,8-trimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-3,4-dihydro-1H-isoquinolin-2-ium-2-yl]propyl] butanedioate dichloride
Indication
Disease Entry ICD 11 Status REF
Spasm MB47.3 Approved [1]
Therapeutic Class
Analgesics
Affected Organisms
Humans and other mammals
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 4 Molecular Weight (mw) 1035.2
Logarithm of the Partition Coefficient (xlogp) 7.4
Rotatable Bond Count (rotbonds) 29
Hydrogen Bond Donor Count (hbonddonor) 0
Hydrogen Bond Acceptor Count (hbondacc) 16
ADMET Property
Clearance
The drug present in the plasma can be removed from the body at the rate of 2.7 mL/min/kg [2]
Half-life
The concentration or amount of drug in body reduced by one-half in 99 minutes (in normal healthy adults) [2]
Metabolism
The drug is not metabolised []
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 0.0452 micromolar/kg/day [3]
Unbound Fraction
The unbound fraction of drug in plasma is 0.53% [2]
Vd
The volume of distribution (Vd) of drug is 0.11-0.43 L/kg []
Chemical Identifiers
Formula
C56H78N2O16+2
IUPAC Name
bis[3-[6,7,8-trimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-3,4-dihydro-1H-isoquinolin-2-ium-2-yl]propyl] butanedioate
Canonical SMILES
C[N+]1(CCC2=CC(=C(C(=C2C1CC3=CC(=C(C(=C3)OC)OC)OC)OC)OC)OC)CCCOC(=O)CCC(=O)OCCC[N+]4(CCC5=CC(=C(C(=C5C4CC6=CC(=C(C(=C6)OC)OC)OC)OC)OC)OC)C
InChI
InChI=1S/C56H78N2O16/c1-57(23-19-37-33-45(65-7)53(69-11)55(71-13)49(37)39(57)27-35-29-41(61-3)51(67-9)42(30-35)62-4)21-15-25-73-47(59)17-18-48(60)74-26-16-22-58(2)24-20-38-34-46(66-8)54(70-12)56(72-14)50(38)40(58)28-36-31-43(63-5)52(68-10)44(32-36)64-6/h29-34,39-40H,15-28H2,1-14H3/q+2
InChIKey
GBLRQXKSCRCLBZ-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
60169
ChEBI ID
CHEMBL4706
CAS Number
133814-18-3
UNII
P40015Y3WW
DrugBank ID
DB01135
TTD ID
D0Y7TO
Drug ADMET Endpoint Profile (DAE)NEW Click to Jump to the Detailed DAE Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Neuronal acetylcholine receptor alpha (NACHRA) TTS5WZF NOUNIPROTAC Antagonist [4]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Doxacurium
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Vecuronium DMP0UK2 Moderate Additive neuromuscular blocking effects by the combination of Doxacurium and Vecuronium. Tonus and reflex abnormality [MB47] [5]
Coadministration of a Drug Treating the Disease Different from Doxacurium (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Clindamycin DM15HL8 Moderate Additive neuromuscular blocking effects by the combination of Doxacurium and Clindamycin. Acne vulgaris [ED80] [6]
Paromomycin DM1AGXN Major Additive neuromuscular blocking effects by the combination of Doxacurium and Paromomycin. Amoebiasis [1A36] [7]
Kanamycin DM2DMPO Major Additive neuromuscular blocking effects by the combination of Doxacurium and Kanamycin. Bacterial infection [1A00-1C4Z] [7]
Fosphenytoin DMOX3LB Moderate Increased metabolism of Doxacurium caused by Fosphenytoin mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [8]
Nadolol DMW6GVL Moderate Additive cardiorespiratory depression effects by the combination of Doxacurium and Nadolol. Essential hypertension [BA00] [9]
Metipranolol DMJMVKI Moderate Additive cardiorespiratory depression effects by the combination of Doxacurium and Metipranolol. Glaucoma [9C61] [10]
Levobetaxolol DMSREPX Moderate Additive neuromuscular blocking effects by the combination of Doxacurium and Levobetaxolol. Glaucoma [9C61] [10]
Levobunolol DMTNFCQ Moderate Additive neuromuscular blocking effects by the combination of Doxacurium and Levobunolol. Glaucoma [9C61] [10]
Carvedilol DMHTEAO Moderate Additive neuromuscular blocking effects by the combination of Doxacurium and Carvedilol. Heart failure [BD10-BD1Z] [9]
Acebutolol DM0TI4U Moderate Additive neuromuscular blocking effects by the combination of Doxacurium and Acebutolol. Hypertension [BA00-BA04] [9]
Penbutolol DM4ES8F Moderate Additive cardiorespiratory depression effects by the combination of Doxacurium and Penbutolol. Hypertension [BA00-BA04] [10]
Nebivolol DM7F1PA Moderate Additive neuromuscular blocking effects by the combination of Doxacurium and Nebivolol. Hypertension [BA00-BA04] [9]
Dexamethasone DMMWZET Moderate Additive neuromuscular blocking effects by the combination of Doxacurium and Dexamethasone. Rheumatoid arthritis [FA20] [11]
Plazomicin DMKMBES Major Additive neuromuscular blocking effects by the combination of Doxacurium and Plazomicin. Urinary tract infection [GC08] [12]
⏷ Show the Full List of 14 DDI Information of This Drug

References

1 Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
2 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
3 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
4 Interaction of nondepolarizing muscle relaxants with M2 and M3 muscarinic receptors in guinea pig lung and heart. Anesthesiology. 1996 Jan;84(1):155-61.
5 Pandit SK, Ferres CJ, Gibson FM, Mirakhur RK "Time course of action of combinations of vecuronium and pancuronium." Anaesthesia 41 (1986): 151-4. [PMID: 2869710]
6 Alahdal O, Bevan DR "Clindamycin-induced neuromuscular blockade." Can J Anaesth 42 (1995): 614-7. [PMID: 7553999]
7 Burkett L, Bikhazi GB, Thomas KC Jr, Rosenthal DA, Wirta MG, Foldes FF "Mutual potentiation of the neuromuscular effects of antibiotics and relaxants." Anesth Analg 58 (1979): 107-15. [PMID: 571233]
8 Liberman BA, Norman P, Hardy BG "Pancuronium-phenytoin interaction: a case of decreased duration of neuromuscular blockade." Int J Clin Pharmacol Ther Toxicol 26 (1988): 371-4. [PMID: 3220609]
9 Chapple DJ, Clark JS, Hughes R "Interaction between atracurium and drugs used in anaesthesia." Br J Anaesth 55 Suppl 1 (1983): s17-22. [PMID: 6688011]
10 Harrah MD, Way WL, Katzung BG "The interaction of d-tubocurarine with antiarrhythmic drugs." Anesthesiology 33 (1970): 406-10. [PMID: 5512329]
11 Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
12 Geha DG, Blitt CD, Moon BJ "Prolonged neuromuscular blockade with pancuronium in the presence of acute renal failure: a case report." Anesth Analg 55 (1976): 343-5. [PMID: 945014]